EFFICACY AND ADVERSE OF EFFECTS MULTI-DRUG RESISTANT PULMONARY TUBERCULOSIS REGIMEN THERAPY A SYSTEMATIC REVIEW FROM RANDOMIZED CONTROL TRIAL
PDF

Keywords

Adverse effect
Efficacy
Multi drug resistant
Pulmonary tuberculosis
Randomized control trial
Systematic literature review

Categories

How to Cite

Said Zubaidy, R. (2025). EFFICACY AND ADVERSE OF EFFECTS MULTI-DRUG RESISTANT PULMONARY TUBERCULOSIS REGIMEN THERAPY A SYSTEMATIC REVIEW FROM RANDOMIZED CONTROL TRIAL. Journal of Research in Pharmacy and Pharmaceutical Sciences, 4(1), 48–54. https://doi.org/10.33533/jrpps.v4i2.12417

Abstract

Multidrug-resistant tuberculosis (MDR-TB) remains a major challenge in global tuberculosis control due to low treatment success rates, long therapy durations, and a high risk of adverse effects. The development of new therapy regimens and additional strategies continues to be evaluated to improve treatment efficacy and safety. This systematic literature review was conducted by examining four randomized controlled trials published between 2015 and 2025, namely the studies by Tang et al., Zhang et al., Ruan et al., and Nyang’wa et al. Articles were selected based on their relevance to the topic of efficacy and adverse effects of MDR-TB therapy regimens. Extracted data included culture conversion rates, treatment success, recovery time, and safety profiles. This review shows that innovations in MDR-TB therapy regimens, whether through the addition of new drugs, the use of adjuvant herbal therapies, or the development of short-course oral regimens—can enhance efficacy while improving treatment safety profiles. These findings support the implementation of new regimens as more effective and safer therapeutic alternatives, with the potential to improve patient adherence in MDR-TB management.

https://doi.org/10.33533/jrpps.v4i2.12417
PDF

References

Bern-Thomas Nyang'wa. (2024). “Short Oral Regimens for Pulmonary Rifampicin-Resistant Tuberculosis (TB-PRACTECAL): An Open-Label, Randomised, Controlled, Phase 2B-3, Multi-Arm, Multicentre, Non-Inferiority Trial.” The Lancet. Respiratory Medicine, vol. 12, no. 2, 1 Feb. 2024, pp. 117–128, https://doi.org/10.1016/s2213-2600(23)00389-2.

Perhimpunan Dokter Paru Indonesia; (2021). Tuberkulosis. Pedoman Diagnosis dan penatalaksanaan di Indonesia.

Soedarsono, S., Mertaniasih, N. M., & Sulistyowati, T. (2020). First line anti-tuberculosis drug resistance pattern in multidrug-resistant pulmonary tuberculosis patients correlate with acid fast bacilli microscopy grading. Indonesian Journal of Tropical and Infectious Disease, 8(2), 83.

Tang, S., (2015). “Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis: Prospective, Multicenter, Randomized Controlled Study in China.” Clinical Infectious Diseases, vol. 60, 20 Jan. 2015, https://doi.org/10.1093/cid/civ027.

Tawfik, G. M., Dila, K. A. S., Mohamed, M. Y. F., Tam, D. N. H., Kien, N. D., Ahmed, A. M., & Huy, N. T. (2019). A step by step guide for conducting a systematic review and meta-analysis with simulation data. Tropical medicine and health, 47(1), 46.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2025 Roqayyah Said Zubaidy